Chronic Hepatitis B infection: Principles of therapy

Kimberly K. Scarsi, Kristin M. Darin

Research output: Contribution to journalReview article

Abstract

Chronic hepatitis B is a global health concern in many resource-limited settings due to perinatal or pediatric hepatitis B virus transmission. In the United States, pediatric infection has been virtually eliminated due to maternal screening during pregnancy and the availability of an effective vaccine. However, young adults remain an at-risk group for hepatitis B virus infection due to sexual transmission and injection drug use. The frequency of progression from acute hepatitis B virus infection to chronic hepatitis B infection depends on multiple factors, including host immune function and age at time of hepatitis B virus infection. Fortunately, there are 7 currently approved therapies for chronic hepatitis B infection, and several emerging therapies that show promise. Despite the availability of these agents, many clinical questions still surround chronic hepatitis B therapy including when to start therapy, which agent is ideal for first and second line therapy, the appropriate duration of therapy, and the role of combination antiviral therapy. This review focuses on agents available for chronic hepatitis B management, including pharmacology, safety and efficacy data, monitoring parameters, and the role for each in chronic hepatitis B therapy in adult patients.

Original languageEnglish (US)
Pages (from-to)359-387
Number of pages29
JournalJournal of Pharmacy Practice
Volume22
Issue number4
DOIs
StatePublished - Aug 1 2009

Fingerprint

Chronic Hepatitis B
Infection
Hepatitis B virus
Virus Diseases
Therapeutics
Pediatrics
Antiviral Agents
Young Adult
Vaccines
Mothers
Pharmacology
Safety
Pregnancy
Injections
Pharmaceutical Preparations

Keywords

  • Chronic hepatitis B
  • Interferon
  • Nucleoside and nucleotide analogues

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Chronic Hepatitis B infection : Principles of therapy. / Scarsi, Kimberly K.; Darin, Kristin M.

In: Journal of Pharmacy Practice, Vol. 22, No. 4, 01.08.2009, p. 359-387.

Research output: Contribution to journalReview article

@article{eb58ceaf530d4849856c057f62b0a03e,
title = "Chronic Hepatitis B infection: Principles of therapy",
abstract = "Chronic hepatitis B is a global health concern in many resource-limited settings due to perinatal or pediatric hepatitis B virus transmission. In the United States, pediatric infection has been virtually eliminated due to maternal screening during pregnancy and the availability of an effective vaccine. However, young adults remain an at-risk group for hepatitis B virus infection due to sexual transmission and injection drug use. The frequency of progression from acute hepatitis B virus infection to chronic hepatitis B infection depends on multiple factors, including host immune function and age at time of hepatitis B virus infection. Fortunately, there are 7 currently approved therapies for chronic hepatitis B infection, and several emerging therapies that show promise. Despite the availability of these agents, many clinical questions still surround chronic hepatitis B therapy including when to start therapy, which agent is ideal for first and second line therapy, the appropriate duration of therapy, and the role of combination antiviral therapy. This review focuses on agents available for chronic hepatitis B management, including pharmacology, safety and efficacy data, monitoring parameters, and the role for each in chronic hepatitis B therapy in adult patients.",
keywords = "Chronic hepatitis B, Interferon, Nucleoside and nucleotide analogues",
author = "Scarsi, {Kimberly K.} and Darin, {Kristin M.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1177/0897190008328692",
language = "English (US)",
volume = "22",
pages = "359--387",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Chronic Hepatitis B infection

T2 - Principles of therapy

AU - Scarsi, Kimberly K.

AU - Darin, Kristin M.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Chronic hepatitis B is a global health concern in many resource-limited settings due to perinatal or pediatric hepatitis B virus transmission. In the United States, pediatric infection has been virtually eliminated due to maternal screening during pregnancy and the availability of an effective vaccine. However, young adults remain an at-risk group for hepatitis B virus infection due to sexual transmission and injection drug use. The frequency of progression from acute hepatitis B virus infection to chronic hepatitis B infection depends on multiple factors, including host immune function and age at time of hepatitis B virus infection. Fortunately, there are 7 currently approved therapies for chronic hepatitis B infection, and several emerging therapies that show promise. Despite the availability of these agents, many clinical questions still surround chronic hepatitis B therapy including when to start therapy, which agent is ideal for first and second line therapy, the appropriate duration of therapy, and the role of combination antiviral therapy. This review focuses on agents available for chronic hepatitis B management, including pharmacology, safety and efficacy data, monitoring parameters, and the role for each in chronic hepatitis B therapy in adult patients.

AB - Chronic hepatitis B is a global health concern in many resource-limited settings due to perinatal or pediatric hepatitis B virus transmission. In the United States, pediatric infection has been virtually eliminated due to maternal screening during pregnancy and the availability of an effective vaccine. However, young adults remain an at-risk group for hepatitis B virus infection due to sexual transmission and injection drug use. The frequency of progression from acute hepatitis B virus infection to chronic hepatitis B infection depends on multiple factors, including host immune function and age at time of hepatitis B virus infection. Fortunately, there are 7 currently approved therapies for chronic hepatitis B infection, and several emerging therapies that show promise. Despite the availability of these agents, many clinical questions still surround chronic hepatitis B therapy including when to start therapy, which agent is ideal for first and second line therapy, the appropriate duration of therapy, and the role of combination antiviral therapy. This review focuses on agents available for chronic hepatitis B management, including pharmacology, safety and efficacy data, monitoring parameters, and the role for each in chronic hepatitis B therapy in adult patients.

KW - Chronic hepatitis B

KW - Interferon

KW - Nucleoside and nucleotide analogues

UR - http://www.scopus.com/inward/record.url?scp=68449090867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449090867&partnerID=8YFLogxK

U2 - 10.1177/0897190008328692

DO - 10.1177/0897190008328692

M3 - Review article

AN - SCOPUS:68449090867

VL - 22

SP - 359

EP - 387

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 4

ER -